Phlebologie, Table of Contents Phlebologie 2018; 47(03): 146-154DOI: 10.1055/s-0038-1657857 Übersichtsarbeiten – Reviews Schattauer GmbH DOAC use in patients with chronic kidney disease An updateDOAK bei Patienten mit chronischen NierenerkrankungenUpdate S. Kücükköylü Department of Medicine, Division of Nephrology, University of Düsseldorf , L. C. Rump Department of Medicine, Division of Nephrology, University of Düsseldorf › Author Affiliations Recommend Article Abstract Full Text PDF Download Keywords KeywordsAtrial fibrillation - dialysis - anticoagulation - calcineurin-inhibitors Schlüsselwörter SchlüsselwörterVorhofflimmern - Dialyse - Antikoagulation - Calcineurin-Hemmer References References 1 Kucukkoylu S, Rump LC. [Renal insufficiency and cardiovascular diseases]. Internist 2012; 53: 791-801. 2 Saran R, Li Y, Robinson B. et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kid Dis 2016; 67: S1-305. 3 Levey AS, de Jong PE, Coresh J. et al. The definition, classification, and prognosis of chronic kid-ney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28. 4 Alonso A, Lopez FL, Matsushita K. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 2946-2953. 5 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988. 6 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-1678. 7 Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: 297-306. 8 Vazquez E, Sanchez-Perales C, Garcia-Garcia F. et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; 76: 324-330. 9 Winkelmayer WC, Patrick AR, Liu J. et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. JASN 2011; 22: 349-357. 10 Piccini JP, Stevens SR, Chang Y. et al. Committee RAS and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013; 127: 224-232. 11 Wizemann V, Tong L, Satayathum S. et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098-1106. 12 Mearns ES, White CM, Kohn CG. et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J 2014; 12: 14. 13 Ansell J, Hollowell J, Pengo V. et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombol 2007; 23: 83-91. 14 Jun M, James MT, Manns BJ. et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 2015; 350: h246. 15 Yang F, Chou D, Schweitzer P. et al. Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. Europace 2010; 12: 1666-1672. 16 Chen JJ, Lin LY, Yang YH. et al. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation - a nation-wide database analyses. Int J Cardiol 2014; 177: 1008-1011. 17 Shah M, Avgil-Tsadok M, Jackevicius CA. et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129: 1196-1203. 18 Chan KE, Giugliano RP, Patel MR. et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. J Am Coll Cardiol 2016; 67: 2888-2899. 19 Herzog CA, Asinger RW, Berger AK. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586. 20 January CT, Wann LS, Alpert JS. et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-76. 21 Bonde AN, Lip GY, Kamper AL. et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014; 64: 2471-2482. 22 Anderson Jr FA, Wheeler HB, Goldberg RJ. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Int Med 1991; 151: 933-938. 23 Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Op Pulm Med 2009; 15: 408-412. 24 Ocak G, Vossen CY, Lijfering WM. et al. Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function. Circulation 2014; 129: 683-691. 25 Mahmoodi BK, Gansevoort RT, Naess IA. et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation 2012; 126: 1964-1971. 26 Cook D, Crowther M, Meade M. et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005; 33: 1565-1571. 27 Lindner G, Funk GC, Pfortmueller CA. et al. D-dimer to rule out pulmonary embolism in renal insufficiency. Am J Med 2014; 127: 343-347. 28 Tsai J, Abe K, Boulet SL. et al. Predictive accuracy of 29-comorbidity index for in-hospital deaths in US adult hospitalizations with a diagnosis of venous thromboembolism. PloS one 2013; 08: e70061. 29 Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol 2012; 68: 757-765. 30 Rankin AJ, McQuarrie EP, Fox JG. et al. Venous Thromboembolism in Primary Nephrotic Syndrome - Is the Risk High Enough to Justify Prophylactic Anticoagulation?. Nephron 2017; 135: 39-45. 31 Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994; 45: 578-585. 32 Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines - application to the individual patient. Kidney Int 2012; 82: 840-856. 33 Lee T, Derebail VK, Kshirsagar AV. et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int 2016; 89: 1111-1118. 34 Negrini S, Pappalardo F, Murdaca G. et al. The antiphospholipid syndrome: from pathophysiology to treatment. Clin Exp Med. 2016 [Epub].. 35 Crowl A, Schullo-Feulner A, Moon JY. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother 2014; 48: 1479-1483. 36 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41. 37 Levey AS, Stevens LA, Schmid CH. et al. A new equation to estimate glomerular filtration rate. Ann Int Med 2009; 150: 604-612. 38 Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Int Med 1999; 130: 461-470. 39 Fernandez-Prado R, Castillo-Rodriguez E, Velez-Arribas FJ. et al. Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation. Am J Med 2016; 129: 1259-1263. 40 Schlieper G, Schwenger V, Remppis A. et al. [Anticoagulation in patients with chronic kidney disease : Recommendations from the working group “Heart-Kidney” of the German Cardiac Society and the German Society of Nephrology]. Internist 2017; 58: 512-521. 41 Maegdefessel L, Spin JM, Azuma J. et al. New options with dabigatran etexilate in anticoagulant therapy. Vascular health and risk management 2010; 06: 339-349. 42 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. 43 Hijazi Z, Hohnloser SH, Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961-970. 44 Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012; 52: 119S-125S. 45 Lehr T, Haertter S, Liesenfeld KH. et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012; 52: 1373-1378. 46 Patel MR, Mahaffey KW, Garg J. et al. and Investigators RA. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891. 47 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747. 48 Fordyce CB, Hellkamp AS, Lokhnygina Y. et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016; 134: 37-47. 49 Granger CB, Alexander JH, McMurray JJ. et al. Committees A and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992. 50 Goto S, Zhu J, Liu L. et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J 2014; 168: 303-309. 51 Hohnloser SH, Hijazi Z, Thomas L. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-2830. 52 Pathak R, Pandit A, Karmacharya P. et al. Metaanalysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol 2015; 115: 323-327. 53 Giugliano RP, Ruff CT, Braunwald E. et al. and Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104. 54 Bohula EA, Giugliano RP, Ruff CT. et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016; 134: 24-36. 55 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507. 56 Chan KE, Edelman ER, Wenger JB. et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131: 972-979. 57 Khadzhynov D, Wagner F, Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with endstage renal disease. Thromb Haemost 2013; 109: 596-605. 58 Wang X, Tirucherai G, Marbury TC. et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628-636. 59 Kufel WD, Zayac AS, Lehmann DF. et al. Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis. Pharmacotherapy 2016; 36: e166-e171. 60 Cohen AT, Harrington RA, Goldhaber SZ. et al. and Investigators A. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016; 375: 534-544. 61 Wannhoff A, Weiss KH, Schemmer P. et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation 2014; 98: e12-13. 62 Vanhove T, Spriet I, Annaert P. et al. Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit 2017; 39: 77-82. 63 Parasrampuria DA, Mendell J, Shi M. et al. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Brit J Pharmacol 2016; 82: 1591-1600. 64 Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016; 172: 315-336. 65 Samuelson BT, Cuker A, Siegal DM. et al. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest 2017; 151: 127-138. 66 AWMF-Leitlinie. 2015 http://www.awmf.org/ uploads/tx_szleitlinien/065-002l_S2k_VTE_2016-01.pdf.
